Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 12Terminated 6Active not recruiting 4Withdrawn 3Unknown 3Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 1CNS 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Meningioma 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Cisplatin 517Radiotherapy 378Cyclophosphamide 368Carboplatin 359Capecitabine 342Paclitaxel 337Oxaliplatin 336Gemcitabine 322Docetaxel 317Fluorouracil 291Drug Therapy 277Bevacizumab 249apatinib 247camrelizumab 219Etoposide 201Irinotecan 183Doxorubicin 181Leucovorin 164Dexamethasone 161pembrolizumab 155Neoadjuvant Therapy 146sintilimab 145anlotinib 140Blood Specimen Collection 140Pemetrexed 138Cytarabine 138toripalimab 133Surgical Procedures, Operative 131Radiosurgery 131S 1 (combination) 125

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × vistusertib × Clear all
NCT02730923 2024-02-13

VICTORIA

Centre Leon Berard

Phase 1/2 Unknown
72 enrolled
Gynecologic

Carcinoma, Endometrial Neoplasms

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown
28 enrolled
CNS

Meningioma

NCT02583542 2020-02-25

TORCMEK

Queen Mary University of London

Phase 1/2 Unknown
118 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡